secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2022-04-20T23:59:59+00:00
Accession:  0001438533-22-000017
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Therapeutics CFO Laura Clague to retire; Christopher Cline named successor effective Aug 31, 2022
--------------------------------------------------------------------------------

- Laura Clague steps down as CFO on August 31, 2022 (or earlier if mutually agreed).
- Christopher Cline, current SVP Investor Relations & Corporate Communications, appointed CFO on that date.
- Clague remains employee through transition until March 31, 2023 at reduced base salary of $330,000 (70% of $471,000).
- Clague eligible for 2022 bonus at 50% target and pro-rata 2023 bonus at 40% target; equity continues vesting.
- Transition requires Clague to sign a general release on termination date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/0001438533-22-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853322000017/tvtx-20220419.htm
  HTML page:      https://secwatch.observer/filing/0001438533-22-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer